FATE THERAPEUTICS INC (FATE): Entry into a Material Definitive Agreement

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 5, 2026, Fate Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), with respect to an at-the-market offering program (the “ATM Pr

Event · Offering · definitive agreement
Instrument
shares of its common stock, par value $0.001 per share
Gross proceeds
$100,000,000
Use of proceeds
Sales Agreement

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 5, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$FATE
Bearish
high confidence
Mentioned
$FATE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$FATEBearishHigh
01

Why it matters

The new agreement replaces the prior program, allowing continued access to capital markets while giving the company discretion over timing and size of issuances.

02

Market read

First‑report primary disclosure of a $100 M financing vehicle for a mid‑cap biotech, likely to influence short‑term price and set a precedent for similar firms.

03

What to watch

Potential covenant terms, pricing discounts, and the ability to draw down funds only at management's discretion could affect timing of cash inflows.

Relevance 6/10Novelty 8/10Timing: today

Background

Fate Therapeutics (NASDAQ:FATE) is a clinical‑stage biotech developing cellular immunotherapies. The company previously used a Jefferies ATM program for up to $100 M.

Company-level read

Ticker impact

$FATEBearishHigh confidence
Context

Fate Therapeutics filed an 8‑K announcing a new $100 million at‑the‑market (ATM) sales agreement with Leerink Partners, replacing a prior $100 million Jefferies agreement.

Expected impact

likely modest downward pressure as investors price in dilution, offset by potential upside from new capital for growth initiatives

Evidence & confidence

Primary SEC filing introduces a sizable financing tool; market typically reacts with slight price dip on dilution concerns, but the capital can fund pipeline progress.

Market effects

Provides a financing template for other small‑cap biotech firms seeking flexible capital, may encourage similar ATM deals.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact beyond niche biotech financing market.

Counterpoint

The ATM could be seen as a sign of cash constraints, suggesting a near‑term need for capital that may pressure the stock.

Key entities

  • Fate Therapeutics, Inc.

    Biotech firm issuing the ATM program.

  • Leerink Partners LLC

    Sales agent for the new ATM offering.

Related articles

$FATEHigh

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be fa

$FATEMed

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN $15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Thera

$FATEMedAI 8/10

Fate Therapeutics, Inc.: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Fate Therapeutics (NASDAQ: FATE) dosed the first patient in its Phase 2 potentially registrational RECLAIM-LN trial of FT819 for refractory moderate-to-severe SLE with Class III or IV lupus nephritis. The single-arm study targets about 53 patients, with complete renal response at Week 26 as the primary endpoint. Enrollment is expected to finish in 15-18 months, by 1H2028.

$FATEMed

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated